Avid Bioservices Inc (CDMO)

[biopharm]

Pfizer network, with Hub presence, teams with UC-San Francisco to develop small molecule drugs

Drugmaker Pfizer Inc. said it is expanding its Centers for Therapeutic Innovation into the development of small-molecule drug candidates through a partnership with the University of California, San Francisco.

http://www.boston.com/businessupdates/2013/05/31/pfizer-network-with-hub-presence-teams-with-san-francisco-develop-small-molecule-drugs/AMWGMhRaMzqUhWq88N065N/story.html

Question to the "science" guys... could Bavi be possibly an addition to these small molecules ... or the patent on the PS-platform, could these small molecules be discovered that could utilize diagnostics of some sort to target PS ?

------------------------------------------------------------------


... partial job description below... but I'm trying to "understand" monoclonal antibodies vs. small molecule drugs and this seems to say that experience with monocolonal antibodies is needed to understand/work with a "small molecule" drug... hence my question above can a mab such as Bavi work with a "small molecule drug".... is that Bavi 2.0 ? or just slap me silly if I can confusing this : )

To be considered for this role you will have experience in the optimisation / scale up of protein modification and conjugation processes. Coupled with this you will have background in the conjugation of monoclonal antibodies to small molecules as well as experience in protein purification and basic HPLC methods.

http://jobs.newscientist.com/job/1401449430/antibody-conjugation-scientist-north-wales/?TrackID=111#sc=rss&me=feed&cm=general
-----------------------------------------------------------------


Pfizer's Xalkori Delays the Worsening of Lung Cancer Vs Chemotherapy

Xalkori is a new drug designed to treat the approximately 5% of non-small cell lung cancer patients who test positive for alterations in a gene known as ALK. Many ALK-positive patients are those who have never smoked and who are younger than most ALK-negative patients with the deadly disease.

Bavi added to Xalkori could further increase results

http://online.wsj.com/article/BT-CO-20130601-701220.html?mod=googlenews_wsj
-----------------------------------------------------------------